30mg Librela Solution for Dogs - 2 Vials

Description

Librela 30mg Injection is a prescription-only veterinary medicine used to help relieve pain associated with osteoarthritis in dogs. It contains bedinvetmab, a canine monoclonal antibody, and it is given as a monthly subcutaneous injection by a veterinary surgeon. Librela 30mg Injection is intended for dogs whose weight and clinical assessment make the 30mg strength appropriate, and your vet will confirm the correct dose before treatment.

Osteoarthritis is a long-term joint disease that can make ordinary activities feel difficult, even when a dog is still eager to join family life. It can affect the hips, elbows, stifles, shoulders, spine or several joints at once, and it often develops gradually as inflammation, cartilage wear and bony change alter how the joint moves. Librela 30mg Injection is not a cure for arthritis, but it may form an important part of a wider mobility plan that also includes controlled exercise, weight management, home adaptations and regular veterinary reviews.

Librela 30mg Injection is used for dogs with osteoarthritis, a degenerative joint condition in which cartilage, synovial fluid, bone and soft tissues around the joint can become painful and less efficient. The condition is common in older dogs, but it may also affect dogs with previous joint injury, hip dysplasia, elbow dysplasia, cruciate ligament disease or long-standing joint strain. Dogs often hide pain well, so owners may first notice small changes rather than obvious crying or yelping, and these changes can be mistaken for normal ageing. A veterinary diagnosis may involve discussion of your dog’s history, gait assessment, joint manipulation, body condition scoring and, where needed, imaging such as radiographs. Signs that may prompt a veterinary assessment include:

• stiffness after rest, especially first thing in the morning;
• limping, lameness or a shortened stride;
• reluctance to climb stairs, jump into the car or get onto furniture;
• slower walks, lagging behind or stopping more often;
• irritability, reduced play or changes in sleeping position.

Librela 30mg Injection works in a different way from many traditional pain-relieving medicines. Bedinvetmab is designed to bind to nerve growth factor, often shortened to NGF, which is involved in pain signalling in osteoarthritic joints. When NGF is neutralised, it is less able to trigger the chain of signals that tells the nervous system a joint is painful. This targeted mechanism helps explain why Librela 30mg Injection is described as a monoclonal antibody therapy rather than a steroid or a non-steroidal anti-inflammatory drug. Because Librela 30mg Injection acts on NGF-mediated pain pathways, it focuses on pain communication rather than directly rebuilding cartilage or reversing the underlying joint changes. As a biological medicine, bedinvetmab is expected to be broken down through normal protein catabolism into smaller peptides and amino acids, which is one reason vets may consider it separately from many conventional oral pain medicines.

The aim of Librela 30mg Injection is to make osteoarthritis pain easier for the dog to live with, so day-to-day movement may become more comfortable. A dog that responds well may seem more willing to rise after resting, walk for a more normal distance, move around the home, or take part in gentle activity. Owners may also notice changes in posture, confidence, sleep quality or willingness to be touched around sore areas, although response varies between individuals and should be judged over time. Rather than looking for a single dramatic change, owners are often encouraged to look for a pattern across several everyday tasks, such as how easily the dog settles, turns, trots, climbs or gets up after sleep. This kind of observation gives the veterinary team useful clinical feedback and helps avoid increasing exercise faster than sore joints and weakened muscles can tolerate. Some dogs may need a second monthly dose before a clearer improvement is seen. If there is little or no improvement after the first two doses, your veterinary surgeon may reassess the diagnosis, review the overall treatment plan or discuss other options. Librela 30mg Injection can be especially useful for owners who prefer a once-monthly clinic-administered treatment rather than daily oral dosing, although suitability must always be decided by a vet.

Librela 30mg Injection is administered under the skin, usually once every month, and the dose is based on body weight.

How does Librela 30mg Injection work?
Librela 30mg Injection works by targeting nerve growth factor, or NGF, a substance involved in pain signalling in arthritic joints. Bedinvetmab binds to NGF so it is less able to activate pain pathways. This may make movement more comfortable without being a steroid or traditional NSAID.

How often is Librela 30mg Injection given?
Librela 30mg Injection is usually given once every month by subcutaneous injection. Your dog’s dose is based on body weight, and some dogs may need a different strength or a combination of vials. Treatment intervals should be set and reviewed by your veterinary surgeon.

How quickly does Librela 30mg Injection work?
Some dogs may show signs of improved comfort within the first week, while others need more time. If response is limited after the first monthly dose, a second dose may still bring improvement. Your vet will normally assess progress using mobility, pain and quality-of-life changes.

Is Librela 30mg Injection an NSAID?
No. Librela 30mg Injection is not a non-steroidal anti-inflammatory drug and it is not a steroid. It is a monoclonal antibody therapy that targets NGF-mediated pain signalling. This makes it different from many daily oral pain medicines used for canine osteoarthritis.

What side effects should I watch for after Librela 30mg Injection?
Contact your vet if your dog seems unwell after Librela 30mg Injection. Possible adverse effects can include injection-site swelling or warmth, vomiting, diarrhoea, reduced appetite, lethargy, increased thirst or urination, incoordination, weakness, hypersensitivity signs or seizures. Prompt advice is important if symptoms are unusual or severe.